Adverse events138

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 138

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	EOSINOPHILIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 Pbo for 7 Days (A)	1	31	1
other	EOSINOPHILIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 400 mg for 7 Days (B)	2	31	2
other	EOSINOPHILIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (C)	0	30	0
other	EOSINOPHILIA	Blood and lymphatic system disorders	Part 1: ABBV-4083/Albendazole 400 mg 3 d; ABBV-4083 400 mg/Albendazole Pbo 4 d; ABBV-4083 Pbo 7 d(D)	2	30	2
other	EOSINOPHILIA	Blood and lymphatic system disorders	Participants Randomized to Receive ABBV-4083 (Arms A, B, C, and D)	5	122	5
other	EOSINOPHILIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 Pbo + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (E)	2	31	2
other	NEUTROPENIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 Pbo for 7 Days (A)	5	31	5
other	NEUTROPENIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 400 mg for 7 Days (B)	2	31	2
other	NEUTROPENIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 400 mg + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (C)	7	30	7
other	NEUTROPENIA	Blood and lymphatic system disorders	Part 1: ABBV-4083/Albendazole 400 mg 3 d; ABBV-4083 400 mg/Albendazole Pbo 4 d; ABBV-4083 Pbo 7 d(D)	2	30	2
other	NEUTROPENIA	Blood and lymphatic system disorders	Participants Randomized to Receive ABBV-4083 (Arms A, B, C, and D)	16	122	16
other	NEUTROPENIA	Blood and lymphatic system disorders	Part 1: ABBV-4083 Pbo + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (E)	2	31	2
other	EYE PRURITUS	Eye disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 Pbo for 7 Days (A)	0	31	0
other	EYE PRURITUS	Eye disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 400 mg for 7 Days (B)	0	31	0
other	EYE PRURITUS	Eye disorders	Part 1: ABBV-4083 400 mg + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (C)	1	30	1
other	EYE PRURITUS	Eye disorders	Part 1: ABBV-4083/Albendazole 400 mg 3 d; ABBV-4083 400 mg/Albendazole Pbo 4 d; ABBV-4083 Pbo 7 d(D)	0	30	0
other	EYE PRURITUS	Eye disorders	Participants Randomized to Receive ABBV-4083 (Arms A, B, C, and D)	1	122	1
other	EYE PRURITUS	Eye disorders	Part 1: ABBV-4083 Pbo + Albendazole 400 mg for 7 Days, Then ABBV-4083 Pbo for 7 Days (E)	2	31	2
other	VISUAL FIELD DEFECT	Eye disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 Pbo for 7 Days (A)	3	31	4
other	VISUAL FIELD DEFECT	Eye disorders	Part 1: ABBV-4083 400 mg + Albendazole Pbo for 7 Days, Then ABBV-4083 400 mg for 7 Days (B)	2	31	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04913610/events

API reference For AI assistants

Adverse events138

Sources 3

Read this list from software.